Spero Therapeutics, Inc.
SPRO · NASDAQ
Company research
Spero Therapeutics, Inc. (Nasdaq: SPRO) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on identifying, developing, and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections and rare diseases. Founded in 2013, the company's lead pipeline candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic in Phase 3 development for complicated urinary tract infections (cUTIs), and SPR720, an oral antimicrobial agent targeting nontuberculous mycobacterial (NTM) pulmonary disease. The company has secured a key licensing agreement with GSK for tebipenem HBr, which provides up to $150 million in pre-launch milestone payments and positions the drug for potential commercialization if approved, alongside additional strategic partnerships with Meiji Seika Pharma and Everest Medicines. With a small but focused team of approximately 25 employees and a market capitalization of roughly $98 million, Spero Therapeutics remains committed to addressing the global health crisis of antibiotic resistance by advancing differentiated therapies in areas of significant unmet medical need.
Research reports
MarketBeat’s SPRO page provides a low MarketRank score, a “Reduce” consensus rating, and highlights rising short interest and cautious sentiment despite inexpensive P/E and reasonable valuation metrics relative to the broader market and medical sector.
Simply Wall St · June 22, 2026Spero Therapeutics (Nasdaq:SPRO) - Stock AnalysisSimply Wall St’s stock analysis report emphasizes that SPRO is trading roughly 78% below its estimated fair value, has recently turned profitable, and offers a detailed fundamental snapshot (Snowflake scores, earnings and revenue metrics, volatility, and peer comparisons) while noting risks such as significant recent insider selling.
Simply Wall St · June 16, 2026Spero Therapeutics (NasdaqGS:SPRO) Stock ValuationThe valuation-focused Simply Wall St report uses a DCF model and relative P/E analysis to argue SPRO is trading well below its estimated future cash flow value, compares its P/E to peers and the biotech industry, and discusses analyst price targets and data sources, framing the stock as undervalued on fundamental metrics.
Sahm Capital (republishing Simply Wall St Analysis) · March 27, 2026Spero Therapeutics (SPRO) Earnings Turn Positive Challenging Bearish Profitability NarrativesThis narrative-style report analyzes SPRO’s swing to trailing profitability, outlines a bull case centered on tebipenem HBr and GSK milestone economics, contrasts it with a bear case focused on concentration risk, modeled revenue declines, and stretched implied future P/E, and concludes with a balanced view on durability of margins and valuation.
KoalaGains · November 4, 2025Spero Therapeutics, Inc. (SPRO) Stock Analysis & Key MetricsKoalaGains offers a deep, Buffett-style fundamental review that characterizes SPRO as an extreme-risk, “all‑or‑nothing” investment reliant on tebipenem HBr, highlighting its narrow moat, prior FDA rejection, fragile financial position, concentrated pipeline, and the speculative nature of the thesis even with validation from the GSK partnership.